| Dr Sonia Ter Kuile, MD | |
|
2740 S Elm Ave, Elm Community Health Center, Fresno, CA 93706-5435 | |
| (559) 457-5200 | |
| (559) 457-5290 |
| Full Name | Dr Sonia Ter Kuile |
|---|---|
| Gender | Female |
| Speciality | General Practice |
| Experience | 15 Years |
| Location | 2740 S Elm Ave, Fresno, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407221021 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | 139452 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| San Mateo Medical Center | San mateo, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| County Of San Mateo | 9032023171 | 242 |
News Archive
For women with breast cancer undergoing radiation therapy, yoga offers unique benefits beyond fighting fatigue, according to new research from The University of Texas MD Anderson Cancer Center.
Wellstar International, Inc., has announced that it has entered into a financing agreement with JMJ Financial to provide the Company with an expected $1.2 million dollars in operational funding over the eighteen months. Details of the financing were contained in the Company's Form 8-K filing with the Securities and Exchange Commission on October 9, 2009.
Experiments in brain-injured rats show that stem cells injected via the carotid artery travel directly to the brain, where they greatly enhance functional recovery, reports a study in the February issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
Ceptaris Therapeutics, Inc., a privately held, specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration has granted marketing approval for the orphan drug VALCHLOR (mechlorethamine) gel for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy.
Keryx Biopharmaceuticals, Inc. today announced that KRX-0401 (perifosine) has received Orphan-Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma. In August, the Company announced that it had reached an agreement with the FDA regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial in relapsed/refractory multiple myeloma and that the study is expected to start by year-end.
› Verified 5 days ago
| Entity Name | County Of San Mateo |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679642326 PECOS PAC ID: 9032023171 Enrollment ID: O20031126000292 |
News Archive
For women with breast cancer undergoing radiation therapy, yoga offers unique benefits beyond fighting fatigue, according to new research from The University of Texas MD Anderson Cancer Center.
Wellstar International, Inc., has announced that it has entered into a financing agreement with JMJ Financial to provide the Company with an expected $1.2 million dollars in operational funding over the eighteen months. Details of the financing were contained in the Company's Form 8-K filing with the Securities and Exchange Commission on October 9, 2009.
Experiments in brain-injured rats show that stem cells injected via the carotid artery travel directly to the brain, where they greatly enhance functional recovery, reports a study in the February issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
Ceptaris Therapeutics, Inc., a privately held, specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration has granted marketing approval for the orphan drug VALCHLOR (mechlorethamine) gel for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy.
Keryx Biopharmaceuticals, Inc. today announced that KRX-0401 (perifosine) has received Orphan-Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma. In August, the Company announced that it had reached an agreement with the FDA regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial in relapsed/refractory multiple myeloma and that the study is expected to start by year-end.
› Verified 5 days ago
| Entity Name | County Of San Mateo |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831268580 PECOS PAC ID: 9032023171 Enrollment ID: O20040123000822 |
News Archive
For women with breast cancer undergoing radiation therapy, yoga offers unique benefits beyond fighting fatigue, according to new research from The University of Texas MD Anderson Cancer Center.
Wellstar International, Inc., has announced that it has entered into a financing agreement with JMJ Financial to provide the Company with an expected $1.2 million dollars in operational funding over the eighteen months. Details of the financing were contained in the Company's Form 8-K filing with the Securities and Exchange Commission on October 9, 2009.
Experiments in brain-injured rats show that stem cells injected via the carotid artery travel directly to the brain, where they greatly enhance functional recovery, reports a study in the February issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
Ceptaris Therapeutics, Inc., a privately held, specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration has granted marketing approval for the orphan drug VALCHLOR (mechlorethamine) gel for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy.
Keryx Biopharmaceuticals, Inc. today announced that KRX-0401 (perifosine) has received Orphan-Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma. In August, the Company announced that it had reached an agreement with the FDA regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial in relapsed/refractory multiple myeloma and that the study is expected to start by year-end.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sonia Ter Kuile, MD Po Box 1559, Bakersfield, CA 93302-1559 Ph: (661) 635-3050 | Dr Sonia Ter Kuile, MD 2740 S Elm Ave, Elm Community Health Center, Fresno, CA 93706-5435 Ph: (559) 457-5200 |
News Archive
For women with breast cancer undergoing radiation therapy, yoga offers unique benefits beyond fighting fatigue, according to new research from The University of Texas MD Anderson Cancer Center.
Wellstar International, Inc., has announced that it has entered into a financing agreement with JMJ Financial to provide the Company with an expected $1.2 million dollars in operational funding over the eighteen months. Details of the financing were contained in the Company's Form 8-K filing with the Securities and Exchange Commission on October 9, 2009.
Experiments in brain-injured rats show that stem cells injected via the carotid artery travel directly to the brain, where they greatly enhance functional recovery, reports a study in the February issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
Ceptaris Therapeutics, Inc., a privately held, specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration has granted marketing approval for the orphan drug VALCHLOR (mechlorethamine) gel for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy.
Keryx Biopharmaceuticals, Inc. today announced that KRX-0401 (perifosine) has received Orphan-Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma. In August, the Company announced that it had reached an agreement with the FDA regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial in relapsed/refractory multiple myeloma and that the study is expected to start by year-end.
› Verified 5 days ago
Timothy Kirkor Atmajian, MD General Practice Medicare: Accepting Medicare Assignments Practice Location: 2363 W Muscat Ave, Fresno, CA 93706 Phone: 559-287-6700 | |
Suzanne B. Cassidy, MD General Practice Medicare: Not Enrolled in Medicare Practice Location: 2900 Fresno St, Suite 101, Fresno, CA 93721 Phone: 559-227-4472 Fax: 559-227-4217 | |
Mr. Sina Scott Rafisolyman, M.D. General Practice Medicare: Not Enrolled in Medicare Practice Location: 2841 Tulare Street, Fresno, CA 93721 Phone: 559-435-3696 Fax: 559-435-3698 | |
Apai Polyudhapoom, General Practice Medicare: Medicare Enrolled Practice Location: 3233 N Chestnut Ave, Ste 102, Fresno, CA 93726 Phone: 559-233-1188 Fax: 559-233-1189 | |
Dr. Cynthia Garcia Mayhay-lopez, M.D. General Practice Medicare: Not Enrolled in Medicare Practice Location: 2900 Fresno St, 106, Fresno, CA 93721 Phone: 559-903-6690 | |
Dr. Juan Guerrero Bautista, M.D. General Practice Medicare: Accepting Medicare Assignments Practice Location: 1805 E Fir Ave, Suite 101, Fresno, CA 93720 Phone: 559-298-9600 Fax: 559-298-9605 | |
Dr. Marc D. Lasher, D.O. General Practice Medicare: Medicare Enrolled Practice Location: 3707 E Shields Ave, Fresno, CA 93726 Phone: 559-229-9040 Fax: 559-229-9060 |